Lucid advances EsoGuard and EsoCheck payment pathways
CMS recommended retaining EsoGuard's gapfill payment basis and the AMA approved a Category III code for EsoCheck, signaling progress in revenue recognition for the company's colorectal cancer screening tests.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed